Free Trial

Puma Biotechnology (PBYI) Competitors

Puma Biotechnology logo
$5.24 -0.05 (-1.02%)
As of 10:38 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

PBYI vs. ADMA, CTMX, TRDA, SPRY, UPB, CRON, NBTX, VALN, PGEN, and SYRE

Should you be buying Puma Biotechnology stock or one of its competitors? The main competitors of Puma Biotechnology include ADMA Biologics (ADMA), CytomX Therapeutics (CTMX), Entrada Therapeutics (TRDA), ARS Pharmaceuticals (SPRY), Upstream Bio (UPB), Cronos Group (CRON), Nanobiotix (NBTX), Valneva (VALN), Precigen (PGEN), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry.

Puma Biotechnology vs. Its Competitors

Puma Biotechnology (NASDAQ:PBYI) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Puma Biotechnology has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500.

Puma Biotechnology currently has a consensus price target of $7.00, indicating a potential upside of 33.69%. ADMA Biologics has a consensus price target of $27.67, indicating a potential upside of 85.78%. Given ADMA Biologics' stronger consensus rating and higher probable upside, analysts clearly believe ADMA Biologics is more favorable than Puma Biotechnology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Puma Biotechnology
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
ADMA Biologics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.25

In the previous week, Puma Biotechnology had 1 more articles in the media than ADMA Biologics. MarketBeat recorded 5 mentions for Puma Biotechnology and 4 mentions for ADMA Biologics. Puma Biotechnology's average media sentiment score of 1.20 beat ADMA Biologics' score of 0.70 indicating that Puma Biotechnology is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Puma Biotechnology
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
ADMA Biologics
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

ADMA Biologics has higher revenue and earnings than Puma Biotechnology. Puma Biotechnology is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Puma Biotechnology$230.50M1.14$30.28M$0.985.34
ADMA Biologics$426.45M8.33$197.67M$0.8617.32

61.3% of Puma Biotechnology shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 23.3% of Puma Biotechnology shares are held by company insiders. Comparatively, 3.7% of ADMA Biologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

ADMA Biologics has a net margin of 44.06% compared to Puma Biotechnology's net margin of 20.38%. Puma Biotechnology's return on equity of 53.15% beat ADMA Biologics' return on equity.

Company Net Margins Return on Equity Return on Assets
Puma Biotechnology20.38% 53.15% 23.51%
ADMA Biologics 44.06%41.01%28.47%

Summary

ADMA Biologics beats Puma Biotechnology on 11 of the 17 factors compared between the two stocks.

Get Puma Biotechnology News Delivered to You Automatically

Sign up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PBYI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PBYI vs. The Competition

MetricPuma BiotechnologyMED IndustryMedical SectorNASDAQ Exchange
Market Cap$263.69M$3.35B$6.02B$10.34B
Dividend YieldN/A2.31%5.73%4.82%
P/E Ratio5.3422.0184.7826.75
Price / Sales1.14471.83598.92130.97
Price / Cash6.0144.9825.7730.18
Price / Book2.7910.3212.476.64
Net Income$30.28M-$52.47M$3.32B$276.55M
7 Day Performance1.08%-0.66%-0.56%-0.93%
1 Month Performance17.14%13.02%8.20%6.04%
1 Year Performance83.72%19.45%75.60%40.02%

Puma Biotechnology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PBYI
Puma Biotechnology
4.0978 of 5 stars
$5.24
-1.0%
$7.00
+33.7%
+85.6%$263.69M$230.50M5.34200Positive News
Gap Up
ADMA
ADMA Biologics
3.4922 of 5 stars
$14.07
-4.0%
$27.67
+96.6%
-15.1%$3.50B$426.45M16.36530
CTMX
CytomX Therapeutics
4.2191 of 5 stars
$3.28
-0.6%
$5.42
+65.1%
+195.7%$544.21M$141.10M5.86170Gap Up
TRDA
Entrada Therapeutics
2.6808 of 5 stars
$5.92
-1.3%
$25.67
+333.6%
-65.4%$228.22M$210.78M-3.33110
SPRY
ARS Pharmaceuticals
3.0782 of 5 stars
$10.27
-0.4%
$33.17
+222.9%
-24.7%$1.02B$89.15M-20.9690
UPB
Upstream Bio
1.9948 of 5 stars
$18.97
+1.8%
$56.50
+197.8%
-8.7%$1.00B$2.37M0.0038Analyst Forecast
Gap Up
CRON
Cronos Group
1.648 of 5 stars
$2.55
-1.2%
N/A+15.4%$987.86M$117.61M51.00450
NBTX
Nanobiotix
1.1938 of 5 stars
$22.78
+11.1%
$11.00
-51.7%
+512.3%$983.31M$39.18M0.00100Gap Down
VALN
Valneva
2.3115 of 5 stars
$11.02
-3.2%
$15.00
+36.1%
+86.5%$978.71M$183.52M-11.24700
PGEN
Precigen
4.4601 of 5 stars
$3.14
-3.4%
$8.25
+162.7%
+257.2%$968.41M$3.92M-7.48190
SYRE
Spyre Therapeutics
2.943 of 5 stars
$16.67
+4.9%
$54.29
+225.6%
-34.1%$959.77M$890K-4.9073News Coverage
Analyst Upgrade

Related Companies and Tools


This page (NASDAQ:PBYI) was last updated on 10/14/2025 by MarketBeat.com Staff
From Our Partners